

May 8, 1964

Dr. Carl F. Beaver  
Assistant Director  
Clinical Investigation  
McNeil Laboratories, Inc.  
Camp Hill Road  
Fort Washington, Pa.

Dear Dr. Beaver:

I was pleased to have an opportunity to meet you in Philadelphia, and again in Los Angeles. Considering the number of friends that I see on both coasts, I can now understand why the stock of major air lines has risen so rapidly in the past year!

The early clinical drug evaluation unit of this institute will be established within the next few weeks, and we would like to consider an initial study with trifluoperidol in a group of chronic schizophrenics. As I indicated to you, we are now in the midst of a long term study of those schizophrenic patients who have failed to respond to a variety of therapies. We are in the midst of another psychotropic compound, butaperazine, and should like to undertake an investigation with one of the butyrophenones. Following the reports of Dr. Lehmann and others, I should like to investigate the clinical efficacy of trifluoperidol in from twelve to twenty patients at multiple dosage levels. We are most interested in evaluating the changes in clinical symptomatology, and associating these with changes in the electroencephalogram. We must, of course, undertake a variety of other laboratory investigations both to complement our studies and to protect our patients.

I am enclosing a completed form FD 1573.

I would be pleased to have you visit St. Louis to discuss this program in greater detail. On such occasion, I think you should again meet Dr. Itil, who is the director of our EEG laboratories, and Dr. Don, who has recently joined my staff and will be responsible for the clinical observations.

Dr. Beaver  
5-8-64  
Page Two

To undertake such a study, I would be grateful if McNeil Laboratories would consider a concomitant grant in aid, to help defray some of the expenses of our laboratories, especially those of the costs of electroencephalography.

Thank you very much for your interest.

Sincerely yours,

Max Fink, M.D.  
Director

MF/jb

Enc.

P.S. In your description of trifluoperidol, on page 5, you describe a report by Delay and Pichot. We would appreciate a copy of this report.